Strand, Vibeke
Pillinger, Michael H.
Oladapo, Abiola
Yousefian, Charis
Brooks, Dani
Kragh, Nana
Funding for this research was provided by:
Sobi
Article History
Received: 23 February 2024
Accepted: 24 June 2024
First Online: 5 August 2024
Declarations
:
: Vibeke Strand declares consulting fees from AbbVie, Alumis, Amgen, AstraZeneca, Atom Biosciences, Bayer, Blackrock, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Citryll, Equillium, Ermium, Fortress Biotech, Genentech/Roche, Gilead, GSK, Horizon, Inmedix, Janssen, Kiniksa, Eli Lilly, Merck, Novartis, Omeros, Pfizer, R-Pharm, RAPT, Regeneron, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sobi, Sorrento, Spherix, and Urica, and participation on a data safety monitoring board or advisory board for AbbVie and AstraZeneca. Michael H. Pillinger declares investigator-initiated research grants paid to institution from Hikma Pharmaceuticals; consulting fees from Sobi, Amgen, Federation Bio, Scilex and Fortress Biotech; and participation on a data safety monitoring board for Horizon Therapeutics. Abiola Oladapo and Nana Kragh are employees of Sobi. Nana Kragh may hold stock/stock options in Sobi. Charis Yousefian and Dani Brooks declare consulting fees to Endpoint Outcomes from Sobi. Current affiliation of Charis Yousefian is Vector Psychometric Group, LLC, Chapel Hill, NC, USA; current affiliation of Dani Brooks is Boston Medical Center, Boston, MA, USA.
: The study received approval from the Western International Review Board-Copernicus Group Institutional Review Board (IRB Protocol #20215052). The investigator and research personnel conducted this study in accordance with ethical principles outlined in the Declaration of Helsinki. All subjects provided informed consent to participate in the study.